#healthcare #Singapore #Respiree #1BioAI

Innovation in Healthcare: Respiree's 1Bio™AI-Acute Approval

Singapore-based health-tech startup Respiree has reached a significant milestone in the world of medical technology by securing approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox. This advanced software solution is classified as Class B software-as-a-medical device (SaMD) and utilizes artificial intelligence and machine learning to assist healthcare professionals in identifying patients at risk of acute deterioration.

The Challenge of Acute Patient Monitoring

In hospital settings, the timely detection of a patient’s acute deterioration is critical. However, conventional early-warning systems often rely on threshold-based methods that struggle with precision, leading to a high volume of false alarms. This not only increases the workload for healthcare professionals but can also divert attention from patients who truly need care. Respiree aims to address these issues with its innovative solution.

How 1Bio™AI-Acute Works

The 1Bio™AI-Acute system is designed to use only essential bedside-recorded vital signs, including pulse rate, respiratory rate, oxygen saturation, and systolic blood pressure, to generate a probability score. This score effectively indicates the likelihood that a patient may require additional monitoring due to potential health deterioration. A higher score suggests a greater need for clinical attention.

Dr. Gurpreet Singh, CEO and Founder of Respiree, expressed that “The advanced AI-driven machine learning models provide significantly greater precision in notifications, which helps reduce unnecessary alerts. This enables healthcare professionals to prioritize their time around quality patient care.”

Availability and Future Expansion Plans

Following this regulatory approval, healthcare professionals can now access the 1Bio™AI-Acute toolbox through Respiree’s 1Bio™ platform. In addition, the recently approved RS001 wearable device further enhances the monitoring capabilities for patients. The comprehensive approval by the HSA signifies a pivotal step for Respiree as it seeks to expand its regulatory approvals to other regions in Asia Pacific (APAC), Australia, and New Zealand (ANZ), as well as in the United States in the upcoming months.

Moreover, the recent approval builds on the success of a validation study that was peer-reviewed and published in the prestigious Mayo Clinic Proceedings, showcasing the efficacy of the 1Bio™AI-Acute system.

About Respiree

Respiree is an innovative health-tech company focused on developing clinically validated AI solutions aimed at managing disease progression. Their products have already received CE marking and regulatory clearances from notable health authorities, including the Therapeutic Goods Administration and the FDA in the United States.

As the landscape of healthcare technology continues to evolve, Respiree’s commitment to precision and efficiency in patient monitoring represents a promising advancement in improving patient outcomes. With the approval of the 1Bio™AI-Acute toolbox, the company is well positioned to lead the charge in the integration of AI technologies within healthcare practices.

In conclusion, the health-tech industry is entering a transformative phase where tools like the 1Bio™AI-Acute can improve monitoring, reduce unnecessary alarms, and ultimately enhance the quality of patient care. This innovation by Respiree stands as a testament to the power of AI to change and revolutionize healthcare practices, promising a future where patient outcomes can be significantly improved through technology.